Atara Biotherapeutics, Inc. Price Today
Atara Biotherapeutics, Inc.
ATRA
Healthcare
$225.34M
💰
Market Cap
0
💸
Price to Earnings
$-2.0
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
7 |
Strong Buy |
3 |
Hold |
3 |
Sell |
1 |
Strong Sell |
1 |
ATRA Price Forecast Target
2.3 👉 31.0 +1248%
ATRA EPS Forecast
-2.0 👉 -1.9 +-3%
Financials
Profit Margin
0 %
Revenue Growth
-83.2 %
Dividend
$ 0
Held Percent
2.6% - Insiders
107.6% - Institutions
-10.2% - Public
Major Fund Holders
-
💰 Blackrock Inc. $26.9M
-
💰 Baupost Group, Inc,.(The) LLC $26.5M
-
💰 Wasatch Advisors LP $24.2M
-
💰 State Street Corporation $23.9M
-
💰 JP Morgan Chase & Company $22.2M
Stock Ideas
Ray Dalio Portfolio
Ray Dalio, a visionary entrepreneur and investment strategist, laid the foundation of Bridgewater with a clear vision in mind. His relentless pursuit of excellence, coupled with an unwavering commitment to innovation, has propelled Bridgewater to be…
George Soros Portfolio
George Soros is a legendary hedge fund manager who made history when he earned 1 billion in 1992 and became known as 'the Man Who Broke the Bank of England'. "With an estimated net worth of 14.2 billion, Soros is ranked 35th on the list of the world…
Charlie Munger Portfolio
Charlie Munger, the renowned investor and Vice Chairman of Berkshire Hathaway, is a true titan in the world of finance. Often referred to as Warren Buffett's right-hand man, Munger's portfolio investment approach is a masterclass in disciplined and …
Howard Marks Portfolio
Meet Howard Marks, the co-founder and lead of Oaktree Capital Management, a Los Angeles-based investment firm that manages roughly $78 billion in investment capital. Marks has an impressive background in distressed debt, high yield bonds, and conver…📮FAQ
Some Frequently Asked Questions.
The Atara Biotherapeutics, Inc. industry is Biotechnology
The Atara Biotherapeutics, Inc. sector is Healthcare
The Atara Biotherapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -1.2
The Atara Biotherapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Atara Biotherapeutics, Inc. is $225.34M
There are total of 75759978 float shares with 107.6% held by Institutions and 2.6% held by insiders
The MAtara Biotherapeutics, Inc. forecasted Earnings per Share EPS is $-1.9
The Atara Biotherapeutics, Inc. Earnings per Share EPS is -2.0
The Atara Biotherapeutics, Inc. company has $63573000 gross profits with 0 profit margins
The Atara Biotherapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Atara Biotherapeutics, Inc. Revenue is $57485000 with -0.832 revenue growth
The price target for Atara Biotherapeutics, Inc. stock is $31.0 for the high target and $2.0 for the low target
The consensus analyst recommendations for Atara Biotherapeutics, Inc. is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Atara Biotherapeutics, Inc. is Hold, with the following breakdown:
- Buy: 7
- Strong Buy: 3
- Hold: 3
- Sell: 1
- Strong Sell: 1
The Beta of Atara Biotherapeutics, Inc. is 1.0
The dividend of Atara Biotherapeutics, Inc. is $0
The dividend yield of Atara Biotherapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Atara Biotherapeutics, Inc. stock are
- Blackrock Inc.
- Baupost Group, Inc,.(The) LLC
- Wasatch Advisors LP
- State Street Corporation
The Atara Biotherapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0